#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ

Rheumatoid vasculitis: what to look for and how to find it #EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH

Acute Dactylitis in #Psoriatic_Arthritis 🔹️1216 patients Canada 🇨🇦 🔹️52% had at least one episode of acute dactylitis in a median 12 years 🔹️Positive association with HLA-B27 and HLA-B27/C02 🔹️No association with HLA-B51 #EULAR2025 @RheumNow OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4

How to treat rheumatoid vasculitis #EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx

#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS

Should we still be worried about lymphoma developing in RA patients? Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk. So what should our approach be? Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz

About #Multidisciplinarity ... Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care #quotes #EULAR2025 #Invitedspeaker #outofthebox @RheumNow @epirheum https://t.co/RG6xpHejv9

#EULAR2025 Abstr#POS0991 RCT showed Adjuvanted Herpes Zoster vaccination appeared safe in #SLE upto 1 year. However, humoral and cellular responses declined over time. Longer follow up needed to ascertain frequency of vaccine to be repeated @RheumNow https://t.co/FcUi1OfBLu

What kills in GCA? Greek national prospective cohort, small numbers and no doubt some channeling bias, but: Steroids (absence of DMARD use) is more of a factor than CV disease in GCA mortality. With new options, all GCA pts should be on something #EULAR2025 POS0960 @RheumNow https://t.co/Wmvf6tEvaF

In PsA, can we better pick IL-17A inhibitor responders (after TNFi failure)? Transcriptomic profiling is going to get better at telling us which pathways are truly important for response to specific treatments POS0232 #EULAR2025 @RheumNow https://t.co/uycuXB0TFK

KORAIL cohort Prediction model for progression of RA-ILD at 3 years A combination of classic clinical parameters incl DA , ILD pattern, ACPA KL-6 with AUC 0.75 HR=34 for progression in High risk group Need validation in an external cohort @RheumNow #EULAR2025 OP0329 https://t.co/LIvn1JCXPq

#digital #ulcers in #scleroderma🎯 Retrospective #iloprost vs #selexipag 👇 BIG advantage of oral #prostacyclin receptor #agonist vs iloprost healing faster ⬇️ulcers Selexipag used in iloprost failures; ⬇️IV access WOW! RCT needed #OP035 #EULAR2025 @RheumNow @eular_org https://t.co/6y9LwIlQkd